Dr. George Lin

Dr. Lin is a cofounder of Biological Mimetics, Inc. (BMI). He has worked in the Department of Hematology/Oncology and Stellar-Chance Laboratory at the University of Pennsylvania, the Wistar Institute in Philadelphia, PA, the National Cancer Institute in Frederick, MD, Procept Inc. in Cambridge, MA, and the Brigham and Women’s Hospital in Boston, MA.

He has extensive experience in designing vaccines against infectious diseases and cancer, and techniques in molecular and cellular biology, virology, immunology, and animal studies. His expertise lies in understanding the mechanisms of viral receptor interactions and is an inventor of vaccine technology entitled, “Novel HIVs useful in vaccine development and HIV drug design” that complements the Company’s Immune Refocusing Technology. Dr. Lin graduated magna cum laude from Harvard University with an A.B. in Biochemistry. He holds an M.D. and Ph.D. in Virology from the University of Pennsylvania School of Medicine and was awarded the Stuart Mudd Award in Microbiology and Balduin Lucke Memorial Prize for meritorious research in medicine and microbiology.

Published works of Dr. Lin (a partial list)

Lin G, Nara PL.
Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein.
Curr HIV Res. 2007 Nov;5(6):514-41. Review.

Lin G, Bertolotti-Ciarlet A, Haggarty B, Romano J, Nolan KM, Leslie GJ, Jordan AP, Huang CC, Kwong PD, Doms RW, Hoxie JA.
Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.
J Virol. 2007 Sep;81(18):9956-66. Epub 2007 Jul 3.

Lin G, Murphy SL, Gaulton GN, Hoxie JA.
Modification of a viral envelope glycoprotein cell-cell fusion assay by utilizing plasmid encoded bacteriophage RNA polymerase.
J Virol Methods. 2005 Sep;128(1-2):135-42.

Nara PL, Lin G.
HIV-1: the confounding variables of virus neutralization.
Curr Drug Targets Infect Disord. 2005 Jun;5(2):157-70. Review.

Lin G, Hoxie JA.
CCR5 mimicry by sulfated human anti-HIV-1 antibodies.
Cell. 2003 Jul 25;114(2):147-8.

Lin G, Simmons G, Pöhlmann S, Baribaud F, Ni H, Leslie GJ, Haggarty BS, Bates P, Weissman D, Hoxie JA, Doms RW.
Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR.
J Virol. 2003 Jan;77(2):1337-46.

Lin G, Baribaud F, Romano J, Doms RW, Hoxie JA.
Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins.
J Virol. 2003 Jan;77(2):931-42.

Turville SG, Cameron PU, Handley A, Lin G, Pöhlmann S, Doms RW, Cunningham AL.
Diversity of receptors binding HIV on dendritic cell subsets.
Nat Immunol. 2002 Oct;3(10):975-83. Epub 2002 Sep 23.

Lin G, Lee B, Haggarty BS, Doms RW, Hoxie JA.
CD4-independent use of Rhesus CCR5 by human immunodeficiency virus Type 2 implicates an electrostatic interaction between the CCR5 N terminus and the gp120 C4 domain.
J Virol. 2001 Nov;75(22):10766-78.

Garrity RR, Rimmelzwaan G, Minassian A, Tsai WP, Lin G, de Jong JJ, Goudsmit J, Nara PL.
Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope.
J Immunol. 1997 Jul 1;159(1):279-89.